Biogen CEO Dr. George A. Scangos ’70 presents an overview of the company's business model, drug development and strategy for future innovation, as well as a discussion of pricing and financial returns for biotechnology companies and the expectations of patients, physicians, investors and politicians.
Biogen is a global biotechnology company that specializes in the discovery, development and delivery of therapies for the treatment of neurodegenerative, hematologic and autoimmune diseases. Scangos is chairman-elect of the Board of Directors of Pharmaceutical Research and Manufacturers of America (PhRMA).